Page last updated: 2024-12-05

sulfosalicylic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Sulfosalicylic acid (SSA) is a white crystalline solid that is soluble in water and alcohol. It is a strong acid and is used in a variety of applications, including the production of dyes, pharmaceuticals, and analytical reagents. SSA is typically synthesized by sulfonation of salicylic acid. The most common synthesis method involves reacting salicylic acid with sulfuric acid in the presence of a catalyst, typically mercury or a mercury salt. SSA is used in the determination of proteins in biological samples, as it forms a colored complex with proteins. It is also used as a reagent for the determination of iron, copper, and other metals. SSA is a powerful anti-inflammatory agent and has been shown to be effective in treating rheumatoid arthritis and osteoarthritis. SSA is also used as a topical antiseptic and antifungal agent. The anti-inflammatory and antimicrobial effects of SSA are attributed to its ability to inhibit the production of inflammatory mediators. Research into SSA is ongoing to explore its potential uses in treating other inflammatory conditions, such as inflammatory bowel disease and psoriasis. SSA is studied because it is a versatile compound with a wide range of applications. Its strong acidic nature, high solubility, and ability to form complexes with various molecules make it an important reagent in chemistry and biology. Its anti-inflammatory and antimicrobial properties also make it a valuable compound for pharmaceutical applications.'

5-sulfosalicylic acid : An arenesulfonic acid that is benzoic acid substituted by a hydroxy at position C-2 and a sulfo group at C-5. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID7322
CHEMBL ID229241
CHEBI ID68555
SCHEMBL ID34766
MeSH IDM0044405

Synonyms (61)

Synonym
ai3-32582
sulfosalicylic acid (van)
ai3-18246
brn 0650741
salicylsulfonic acid (van)
sulphosalicylic acid (van)
nsc 190565
kalcolor anodizing acid
cp 18121
einecs 202-555-6
5-sulphosalicylic acid
nsc4741
2-hydroxybenzoic-5-sulfonic acid
sulphosalicylic acid
2-hydroxy-5-sulfobenzoic acid
salicylic acid, sulfo-
benzoic acid, 2-hydroxysulfo-
salicylsulfonic acid
sulfosalicylic acid
benzoic acid, 2-hydroxy-5-sulfo-
wln: wsqr dq cvq
5-sulfosalicylic acid
3-carboxy-4-hydroxybenzenesulfonic acid
97-05-2
salicylic acid, 5-sulfo-
nsc-4741
nsc190565
nsc-190565
2-hydroxy-5-sulfo-benzoic acid
5-sulfosalicylate
inchi=1/c7h6o6s/c8-6-2-1-4(14(11,12)13)3-5(6)7(9)10/h1-3,8h,(h,9,10)(h,11,12,13
STK301570
AC-11271
S0830
sulfosalicylic
chebi:68555 ,
CHEMBL229241 ,
bdbm50219498
AKOS000120294
A845677
4-11-00-00702 (beilstein handbook reference)
l8xed79u3u ,
unii-l8xed79u3u
BBL008587
sulfosalicylic acid [who-dd]
sulfosalicylic acid [mi]
FT-0620777
SCHEMBL34766
5-sulfo-salicylic acid
sulfo salicylic acid
5-sulfosalicyclic acid
DTXSID7059145
W-100120
2-hydroxysulfo-benzoic acid
2-hydroxysulfo-benzoate
Q238569
EN300-20563
2-hydroxy-5-sulfobenzoicacid
CS-0013816
HY-B1785
Z104478882

Research Excerpts

Overview

Sulfosalicylic acid is a typical pharmaceutical and personal care product with high toxicity, environmental persistence, and low biodegradability.

ExcerptReferenceRelevance
"Sulfosalicylic acid is a typical pharmaceutical and personal care product with high toxicity, environmental persistence, and low biodegradability. "( Base-metal oxide semiconductor electrodes for PPCP degradation: Ti-doped α-Fe
Du, S; Leng, W; Tan, M; Wu, D; Zhang, S, 2023
)
2.35

Toxicity

ExcerptReferenceRelevance
"Cutaneous toxicity is the most evident adverse effect of epidermal growth factor receptor (EGFR) inhibitors because of the specific role played by EGFR in skin biophysiology."( Clinical management of cutaneous toxicity of anti-EGFR agents.
Monti, M; Motta, S,
)
0.13

Compound-Compound Interactions

ExcerptReferenceRelevance
" The use of 2D-LC combined with SSA precipitation allowed development of a robust, sensitive and rapid quantification assay."( Quantitation of 10 antibiotics in plasma: Sulfosalicylic acid combined with 2D-LC-MS/MS is a robust assay for beta-lactam therapeutic drug monitoring.
Boubekeur, L; Bourgogne, E; Chaussenery-Lorentz, O; Maubert, MA; Maury, E; Palayer, M; Pilon, A; Urbina, T, 2023
)
1.17

Bioavailability

ExcerptReferenceRelevance
" In this study, the triple-lumen perfusion method was used to measure the rate of absorption of trace quantities of selenium (50 micrograms/liter in a physiological electrolyte solution) from the jejunum when given as D,L-selenomethione, D,L-selenocystine, or sodium selenite to healthy dogs in vivo."( Selenium absorption by canine jejunum.
Barbezat, GO; Reasbeck, PG; Robinson, MF; Thomson, CD; Weber, FL, 1985
)
0.27

Dosage Studied

ExcerptRelevanceReference
" Feedback to clinicians was reduced to 24 h, thus allowing rapid dosage adjustment."( Quantitation of 10 antibiotics in plasma: Sulfosalicylic acid combined with 2D-LC-MS/MS is a robust assay for beta-lactam therapeutic drug monitoring.
Boubekeur, L; Bourgogne, E; Chaussenery-Lorentz, O; Maubert, MA; Maury, E; Palayer, M; Pilon, A; Urbina, T, 2023
)
1.17
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
arenesulfonic acidOrganic derivatives of sulfonic acid in which the sulfo group is linked directly to carbon of an aryl group.
benzoic acidsAny aromatic carboxylic acid that consists of benzene in which at least a single hydrogen has been substituted by a carboxy group.
phenolsOrganic aromatic compounds having one or more hydroxy groups attached to a benzene or other arene ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Vitamin B1/Thiamine Metabolism819

Protein Targets (3)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Carbonic anhydrase 1Homo sapiens (human)IC50 (µMol)420.00000.00582.14107.9000AID349140
Carbonic anhydrase 1Homo sapiens (human)Ki770.00000.00001.372610.0000AID349144
Carbonic anhydrase 2Homo sapiens (human)IC50 (µMol)290.00000.00021.10608.3000AID349141
Carbonic anhydrase 2Homo sapiens (human)Ki1,920.00000.00000.72369.9200AID349145
Tyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)IC50 (µMol)1,000.00000.00053.49849.7600AID289410
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (39)

Processvia Protein(s)Taxonomy
one-carbon metabolic processCarbonic anhydrase 1Homo sapiens (human)
morphogenesis of an epitheliumCarbonic anhydrase 2Homo sapiens (human)
positive regulation of synaptic transmission, GABAergicCarbonic anhydrase 2Homo sapiens (human)
positive regulation of cellular pH reductionCarbonic anhydrase 2Homo sapiens (human)
angiotensin-activated signaling pathwayCarbonic anhydrase 2Homo sapiens (human)
regulation of monoatomic anion transportCarbonic anhydrase 2Homo sapiens (human)
secretionCarbonic anhydrase 2Homo sapiens (human)
regulation of intracellular pHCarbonic anhydrase 2Homo sapiens (human)
neuron cellular homeostasisCarbonic anhydrase 2Homo sapiens (human)
positive regulation of dipeptide transmembrane transportCarbonic anhydrase 2Homo sapiens (human)
regulation of chloride transportCarbonic anhydrase 2Homo sapiens (human)
carbon dioxide transportCarbonic anhydrase 2Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 2Homo sapiens (human)
positive regulation of JUN kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein dephosphorylationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of signal transductionTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of signal transductionTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
actin cytoskeleton organizationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of endocytosisTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of vascular endothelial growth factor receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulum unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of intracellular protein transportTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cellular response to unfolded proteinTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
peptidyl-tyrosine dephosphorylationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
platelet-derived growth factor receptor-beta signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
IRE1-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor recyclingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of MAP kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of insulin receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of type I interferon-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
growth hormone receptor signaling pathway via JAK-STATTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of protein tyrosine kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of ERK1 and ERK2 cascadeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of hepatocyte growth factor receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of IRE1-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of PERK-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
peptidyl-tyrosine dephosphorylation involved in inactivation of protein kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of receptor catabolic processTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (16)

Processvia Protein(s)Taxonomy
arylesterase activityCarbonic anhydrase 1Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 1Homo sapiens (human)
protein bindingCarbonic anhydrase 1Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 1Homo sapiens (human)
hydro-lyase activityCarbonic anhydrase 1Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 1Homo sapiens (human)
arylesterase activityCarbonic anhydrase 2Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 2Homo sapiens (human)
protein bindingCarbonic anhydrase 2Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 2Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 2Homo sapiens (human)
RNA bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
zinc ion bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
enzyme bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein kinase bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
receptor tyrosine kinase bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cadherin bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
ephrin receptor bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein phosphatase 2A bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
non-membrane spanning protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (14)

Processvia Protein(s)Taxonomy
cytosolCarbonic anhydrase 1Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 1Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
cytosolCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
myelin sheathCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 2Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
plasma membraneTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
mitochondrial matrixTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
early endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulumTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytosolTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
mitochondrial cristaTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endosome lumenTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
sorting endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmic side of endoplasmic reticulum membraneTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein-containing complexTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulumTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
early endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID289410Inhibition of PTP1B2007Bioorganic & medicinal chemistry, Oct-15, Volume: 15, Issue:20
Mono- and disalicylic acid derivatives: PTP1B inhibitors as potential anti-obesity drugs.
AID349144Inhibition of human carbonic anhydrase 1 esterase activity by competitive Lineweaver-Burke plot2008Bioorganic & medicinal chemistry, Oct-15, Volume: 16, Issue:20
In vitro inhibition of salicylic acid derivatives on human cytosolic carbonic anhydrase isozymes I and II.
AID349145Inhibition of human carbonic anhydrase 2 esterase activity by non-competitive Lineweaver-Burke plot2008Bioorganic & medicinal chemistry, Oct-15, Volume: 16, Issue:20
In vitro inhibition of salicylic acid derivatives on human cytosolic carbonic anhydrase isozymes I and II.
AID349141Inhibition of human carbonic anhydrase 2 esterase activity by spectrophotometry2008Bioorganic & medicinal chemistry, Oct-15, Volume: 16, Issue:20
In vitro inhibition of salicylic acid derivatives on human cytosolic carbonic anhydrase isozymes I and II.
AID349140Inhibition of human carbonic anhydrase 1 esterase activity by spectrophotometry2008Bioorganic & medicinal chemistry, Oct-15, Volume: 16, Issue:20
In vitro inhibition of salicylic acid derivatives on human cytosolic carbonic anhydrase isozymes I and II.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (157)

TimeframeStudies, This Drug (%)All Drugs %
pre-199068 (43.31)18.7374
1990's21 (13.38)18.2507
2000's31 (19.75)29.6817
2010's29 (18.47)24.3611
2020's8 (5.10)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 47.84

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index47.84 (24.57)
Research Supply Index5.13 (2.92)
Research Growth Index4.51 (4.65)
Search Engine Demand Index80.13 (26.88)
Search Engine Supply Index2.14 (0.95)

This Compound (47.84)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.60%)5.53%
Reviews2 (1.20%)6.00%
Case Studies4 (2.40%)4.05%
Observational0 (0.00%)0.25%
Other160 (95.81%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]